HIMS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $0.09 | - | - |
| Q2'26 | $0.11 | $-0.10 | -187.1% |
| Q1'26 | $0.13 | $-0.18 | -235.8% |
| Q4'25 | $0.25 | $0.07 | -71.9% |
| Q3'25 | $0.10 | $0.06 | -41.0% |
| Q2'25 | $0.16 | $0.17 | +3.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $809M | - | - |
| Q2'26 | $714M | $753M | +5.5% |
| Q1'26 | $629M | $608M | -3.4% |
| Q4'25 | $653M | $618M | -5.3% |
| Q3'25 | - | $599M | - |
| Q2'25 | - | $545M | - |
Market Data
HIMS Stock Snapshot
HIMS is currently trading at $32.32, giving Hims & Hers Health, Inc. a market cap of 6.71B and a P/E ratio of 52.3. Today's range spans $30.73–$32.51, with shares opening at $31.29 and moving up $1.24 (4.0%) from the prior close. DailyIQ's technical score sits at 18/100 (SELL) with a news sentiment reading of 54/100.
Over the past year HIMS has traded between $13.74 and $65.30 - the current price is +135.2% off the 52-week low and -50.5% from the high. 24 analysts cover the stock with a Hold consensus and a mean 12-month target of $31.23 (range $23.00–$42.00), implying downside of -3.4%.
The technical setup for Hims & Hers Health, Inc. (HIMS) (small-cap, 6.71B market cap, Healthcare) is in negative territory: 18/100, SELL, with neutral sentiment at 54/100. Price: $32.32 (in the lower half of its 52-week range). The current P/E ratio stands at 52.3. The 52-week range of $13.74–$65.30 defines the boundaries, and the SELL signal at this size often means that the marginal buyer has stepped back entirely - leaving price action vulnerable to any incremental selling.
Small-cap Healthcare names with SELL technicals (18/100) and neutral sentiment (54/100) like HIMS tend to experience sentiment-driven re-ratings more sharply in both directions. At $32.32 (in the lower half of its 52-week range in $13.74–$65.30), the current setup suggests a stock that needs a material positive catalyst, not incremental improvement, to reverse the technical and sentiment readings that now define the 6.71B market cap trajectory.
Company Insights: Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health, Inc. (HIMS) reported Q1 2026 revenue of $608 million, a modest 3 % increase from the $618 million recorded in Q4 2025. Despite the revenue uptick, EPS fell sharply to a loss of $0.18 from the $0.07 profit in Q4 2025, highlighting the company’s earnings volatility. The company’s telehealth platform continues to drive consistent top‑line growth, but margin compression has intensified amid rising cost of prescription and OTC product sourcing. Legal challenges, notably the FTC lawsuit over patient data usage, have added uncertainty to the operating environment. Nonetheless, institutional interest is evident, with BlackRock acquiring 26.5 million shares, signaling confidence in the long‑term model.
Peptide Potential
FDA advisory committee approval could unlock six new peptide drug categories, expanding HIMS’ prescription portfolio and potentially boosting high‑margin revenue streams.
The acquisition of a California peptide manufacturing facility positions HIMS to scale production, reduce third‑party costs, and meet anticipated demand from the newly approved categories.
Early revenue projections indicate peptides could contribute up to 10 % of total sales by 2028, offering a high‑margin growth engine that may offset current earnings volatility.
Legal Headwinds
FTC litigation over patient data usage introduces regulatory risk that could result in costly settlements or operational restrictions, impacting future cash flows.
Morningstar’s assessment of a 'very high' uncertainty underscores the potential for significant legal expenses that could erode profitability if the case is prolonged.
The lawsuit also threatens brand trust, potentially reducing new subscriber acquisition and slowing growth momentum across HIMS’ telehealth and OTC product lines.
Telehealth Moat
HIMS’ direct‑to‑consumer telehealth platform delivers prescription and OTC products through a seamless mobile app, creating a convenient customer experience that encourages repeat visits.
The integrated Labs service provides personalized health insights, fostering deeper patient engagement and generating ancillary revenue from diagnostic testing.
Despite competitive pressure, the platform’s subscription model supports predictable recurring revenue streams across multiple wellness categories, enhancing earnings stability.
Valuation Premium
With a forward P/E of 56.96, HIMS trades above the peer average of 53.0, reflecting premium expectations for future growth amid earnings volatility.
The current price sits 39.5 % below the 52‑week high, yet remains 187.6 % above the low, indicating a wide valuation range that may appeal to value‑seeking investors.
Analyst consensus targets suggest a modest upside of 8 % from today, while the high target implies up to 26 % upside if earnings stabilize and legal risks subside.
Momentum Reversal
Six‑month returns of 44.0 % demonstrate a recent rebound after a year‑to‑date decline of –5.5 %, signaling potential short‑term upside if momentum persists.
Short‑term price movement may reflect market anticipation of the upcoming Q2 earnings release and potential peptide revenue, creating a window for opportunistic entry.
However, sustained upside requires a turnaround in earnings quality and resolution of legal risks to prevent a repeat of the 4‑week losing streak observed earlier this year.
Subscription Growth
HIMS’ subscription services, including AI weight‑loss care, aim to generate recurring revenue and improve customer lifetime value across its wellness product portfolio.
The expansion into AI‑driven wellness offerings could diversify the revenue mix beyond traditional prescription sales, reducing concentration risk.
Early adoption metrics show a steady increase in active subscribers, supporting the company’s long‑term growth narrative and potential for higher margin returns.
Capital Allocation
The company has not disclosed a formal buyback program, limiting immediate shareholder returns compared to peers that routinely return excess capital to investors.
Capital deployment decisions will be critical once earnings normalize, as investors anticipate potential dividends or share repurchases that could enhance shareholder value.
Until a clear capital allocation strategy emerges, the stock’s valuation may remain sensitive to earnings volatility and market sentiment shifts.
Positioning HIMS
Positioning HIMS should focus on a disciplined entry near the 52‑week low, where the current price is 187.6 % above the trough, offering a potential upside if the company resolves its earnings volatility. Consider adding exposure when the share price approaches the analyst consensus target of $29.23, as this level represents a modest 8 % upside from today and may signal a bottoming point. Reduce holdings if the stock trades near the high target of $40.00 or if the 52‑week high of $65.30 is approached, as these levels imply limited upside and heightened risk from legal challenges. Pay close attention to the Q2 earnings release and FDA peptide guidance, which could materially alter the valuation narrative. Adjust position sizing to reflect the stock’s beta and your portfolio’s technology exposure, ensuring that volatility does not disproportionately impact overall risk.
Key Metrics for HIMS
HIMS’s valuation hinges on the interplay between its direct‑to‑consumer prescription sales, the emerging peptide pipeline, and the volatility of its earnings. Investors must gauge how revenue growth, margin dynamics, and market sentiment converge to justify the current premium. The company’s ability to convert telehealth traffic into profitable prescriptions is the engine that drives its multiple, while the FDA’s peptide decision could reshape its revenue mix. These metrics collectively reveal whether the market’s optimism is grounded in sustainable fundamentals or merely chasing short‑term momentum.
Prescription Revenue Growth: Quarterly revenue growth remains the lifeblood of HIMS’s telehealth model. In Q4 2025 the company generated $618 million versus a $653 million estimate, a 3% quarter‑over‑quarter rise but a 2% year‑over‑year decline. The subsequent Q1 2026 revenue of $608 million fell short of the $629 million forecast, underscoring a slowdown in new prescription uptake. A healthy trajectory would see growth above 5% QoQ, while a persistent decline signals saturation or pricing pressure. Historically, revenue beats have nudged the stock higher, whereas misses have triggered sell‑offs. Watch the Q2 2026 guidance for any shift in the sales pipeline or pricing strategy that could reverse the downward trend.
Peptide Pipeline Progress: The recent FDA recommendation to add six peptides to the 503A Bulk Drug Substances List could unlock a new revenue stream for HIMS. Coupled with the company’s acquisition of a California peptide manufacturing facility, the firm is positioning itself to capitalize on a niche, high‑margin product line. Positive regulatory outcomes would broaden the prescription portfolio beyond sexual health and skincare, potentially improving gross margins. Delays or rejections, however, would stall the anticipated upside and keep the company reliant on its existing, lower‑margin categories. The market has reacted favorably to any peptide‑related news, with the stock rallying on FDA announcements. Upcoming FDA rulemaking and the first commercial launch dates will be critical checkpoints for investors.
Profitability Pulse: HIMS’s earnings swings paint a vivid picture of its profitability volatility. The company posted a loss of $0.18 per share in Q1 2026, a sharp reversal from the $0.07 EPS beat in Q4 2025. Earlier quarters showed modest gains: $0.06 in Q3 2025, $0.17 in Q2 2025, $0.20 in Q1 2025, and $0.11 in Q4 2024. This pattern of oscillating EPS reflects the tension between expanding sales and tightening margins. When the company beats expectations, the stock typically gains momentum, but misses often trigger a sharp pullback. Investors should monitor the upcoming earnings release for guidance on cost controls and margin recovery.
Consensus Gap: Analyst consensus places HIMS’s fair value between $21 and $40, a spread that signals divergent expectations. The mean target of $29.23 sits well above the current price of $31.67, yet the high of $40 suggests a bullish outlook for some analysts. The low of $21 indicates that a portion of the market views the company as overvalued or facing significant risks. When the stock trades near the upper end of the range, it may be due for a correction; proximity to the lower end could present a buying opportunity. The wide spread also highlights the uncertainty surrounding the peptide pipeline and regulatory outcomes.
Momentum Shift: Price performance over the past year has been a mixed bag, reflecting the market's ambivalence. The stock has slipped 10.7% in the last month, rebounded 23.7% over three months, yet declined 5.5% over the year. This volatility suggests that short‑term sentiment is heavily influenced by earnings releases and regulatory news. A sustained 3‑month rally could signal renewed confidence, but the negative annual return warns of underlying valuation concerns. Watching the next quarterly earnings for any shift in the earnings trend will help determine whether the momentum is a temporary flare or a new direction.
Risk Factors
Hims & Hers’ risk profile blends regulatory uncertainty, legal exposure, and earnings volatility, with each factor capable of compressing the valuation multiple by 10‑15% if triggered simultaneously. The most actionable risks are those with near‑term catalysts, such as pending FDA approvals and litigation outcomes. Market sentiment remains fragile, reflected in recent price declines and analyst disagreement over growth prospects.
- Peptide Pipeline Uncertainty
Delays in FDA approval for the newly added peptides could stall the projected revenue lift. The company announced acquisition of a California peptide manufacturing facility, but regulatory clearance remains pending. A delay would postpone the expected margin expansion from higher‑priced specialty drugs. In a stress scenario, revenue could fall 5‑10% in the next 12 months, while gross margin might compress by 1‑2 percentage points. Leading indicators include FDA docket updates, FDA advisory committee meeting dates, and the status of the 503A Bulk Drug Substances List. The risk would likely materialize if the FDA postpones or rejects the peptide listing during the next fiscal quarter.
- FTC Data‑Privacy Litigation
The FTC lawsuit over patient data usage introduces a legal and financial tail risk. If the court finds violations, Hims could face a settlement of tens of millions and increased compliance costs. Such a settlement would hit operating income by 5‑10% and could trigger a downgrade in credit ratings. The company’s data‑privacy policies are already under scrutiny, and any adverse ruling would amplify reputational damage. Watch for court filings, settlement announcements, and regulatory guidance on telehealth data handling. The impact would likely unfold over the next 6‑12 months as litigation costs accrue and settlement terms are finalized.
- Earnings Volatility from Prescription Mix
Quarterly swings in prescription sales have already pushed EPS from a 0.07 profit to a 0.18 loss. The miss in Q1 2026, where EPS fell $0.25 below estimates, highlights sensitivity to drug pricing and reimbursement changes. A further decline in prescription volume would compress gross margin by 1‑2 points and reduce operating leverage. The company’s reliance on high‑margin sexual health products makes it vulnerable to payer policy shifts. Key indicators include changes in Medicare Part D formulary status and shifts in consumer spending on telehealth prescriptions. This risk would likely manifest if reimbursement rates drop or if a competitor launches a lower‑price alternative within the next 6 months.
- Analyst Target Spread Disagreement
The 19‑point spread between the highest and lowest analyst targets signals divergent views on the company's growth trajectory. Some analysts emphasize the potential upside of the peptide pipeline, while others focus on the current earnings volatility and regulatory uncertainty. If the higher end of the range proves unattainable, the stock could trade below the mean target, eroding investor confidence. Conversely, a strong execution of the peptide strategy could justify the upper end, leading to a rally. Monitoring analyst revisions and earnings guidance will provide early clues about which side of the spread is gaining traction. The divergence could widen during the next earnings cycle if the company fails to meet revenue expectations.
- Momentum Erosion from Recent Price Decline
A 10.7% drop in the past month has already eroded market confidence, hinting at potential short‑term volatility. The decline followed a broader sell‑off in the telehealth sector and concerns over the FTC lawsuit. If the price continues to slide, the stock may fall below its 12‑month moving average, triggering stop‑loss orders. This could compress the valuation multiple by 10‑15% if the market interprets the decline as a sign of structural weakness. Leading indicators include the 20‑day moving average crossover, volume spikes, and analyst downgrades. The momentum erosion is likely to intensify if the company fails to provide a clear turnaround plan within the next quarter.
What Moves HIMS Stock?
Hims & Hers’ share price is currently dominated by the uncertainty surrounding a high‑profile FTC lawsuit, which has already pushed the stock into a four‑week losing streak. While revenue has grown steadily, climbing from $481 million in Q4 2024 to $618 million in Q4 2025, the company’s earnings volatility and looming legal costs keep the valuation under pressure. Recent developments such as the FDA peptide recommendation and the launch of an AI‑driven weight‑loss program represent underappreciated upside catalysts. With a falling sentiment score of 63, a 68 tech score, and a 6‑month price return of 44%, the market is poised to react sharply to any shift in these drivers.
Legal Overhang
The FTC lawsuit targeting Hims & Hers for patient data use has thrust regulatory scrutiny into the spotlight. If the court finds the company liable, settlement costs could be substantial, eating into cash reserves. Such legal overhang also dampens investor appetite, as uncertainty about future earnings grows. The lawsuit has already triggered a 4‑week losing streak, underscoring the market’s sensitivity to this risk.
Morningstar’s analysis labeled the lawsuit a “very high uncertainty” factor, citing a potential costlier settlement. The firm maintained its $23 fair‑value estimate, implying a 15% downside from current levels. The FTC filing, coupled with the FTC’s nearly three‑year investigation, has amplified the perceived risk. The legal overhang has already manifested in a decline in sentiment, now falling.
Shares have reflected this pressure, sliding into a 4‑week losing streak and trading near the 52‑week low. A 15% downside implied by analysts suggests the market is pricing in potential litigation costs. Technical indicators show a 68 tech score, hinting at short‑term volatility. Any court ruling or settlement announcement could trigger a swift price correction.
Peptide Upside
The FDA Pharmacy Compounding Advisory Committee’s recommendation to add six peptides to the 503A Bulk Drug Substances List opens a new revenue channel. Hims & Hers’ acquisition of a California peptide manufacturing facility positions it to capitalize on this opportunity. Peptides typically command higher margins than generic sexual‑health products, potentially improving profitability. This pipeline represents a tangible upside that is currently underappreciated by the market.
BlackRock’s purchase of 26.5 million shares signals institutional confidence in the company’s growth prospects. The FDA advisory committee’s recommendation is a concrete regulatory win that could accelerate peptide commercialization. The company’s recent acquisition of a manufacturing facility demonstrates operational readiness. These events collectively suggest the peptide upside is moving from theoretical to actionable.
If the peptide pipeline materializes, the share price could lift beyond the current 15% downside implied by analysts. Positive FDA rulemaking or early product launch signals would likely prompt a rally. Monitoring Q2 earnings for guidance on peptide revenue will provide early clues. The market remains cautious, but the potential upside could offset legal headwinds.
AI Weight Loss
Hims & Hers launched an AI‑driven weight‑loss care program, tapping into the booming digital health market. The platform leverages data analytics to personalize diet and exercise plans, creating high customer engagement. Weight‑loss demand has shown resilience, especially among consumers seeking convenient, tech‑enabled solutions. This new offering could diversify revenue beyond sexual‑health products.
Recent headlines highlight the launch and early momentum, with analysts noting a potential lift before Q2 earnings. The company’s 3‑month price return of 23.7% indicates the market has already priced in some of this optimism. Early adopters have reported high satisfaction, suggesting strong repeat‑purchase potential. The AI weight‑loss program is still in its infancy, so the upside remains speculative.
Positive momentum from the AI weight‑loss launch can temporarily lift the share price ahead of earnings. A pre‑earnings rally would likely be followed by a reassessment once guidance is released. Watch the 1‑month price return; a reversal could signal fading enthusiasm. If the program scales, it could become a new growth engine, potentially shifting the valuation multiple.
Earnings Volatility
Hims & Hers’ business model delivers steady revenue growth, yet earnings have swung dramatically due to cost structure and margin pressure. The company’s expenses rise with product expansion, but the high‑margin peptide line has yet to fully offset these costs. This volatility makes the share price highly sensitive to earnings guidance and actual results. The mismatch between revenue growth and EPS performance creates a risk premium in the valuation.
Earnings history shows a pattern of beats in Q1 and Q2 2025, followed by misses in Q3 and Q4 2025, and a loss in Q1 2026. Revenue rose from $481 million in Q4 2024 to $618 million in Q4 2025, yet EPS fell from $0.07 to a loss of $0.18. The 6‑month price return of 44% reflects the market’s reaction to this earnings volatility. Analysts have highlighted the risk of further EPS deterioration if costs rise faster than revenue.
Guidance that undercuts expectations can trigger immediate price drops, while better‑than‑expected earnings can spark a rally. The stock’s 1‑year return of –5.5% underscores the cumulative effect of earnings swings. Monitoring the Q2 earnings release will be critical for assessing whether the volatility persists. A clear earnings trajectory could reduce the risk premium and support a higher valuation.
Key insight: The most critical factor for Hims & Hers remains the legal overhang; any adverse ruling could negate the upside from peptides and AI weight‑loss. If the peptide pipeline and AI program deliver on their promises, they could offset the litigation risk and lift the valuation. However, the company’s earnings volatility will continue to create short‑term price swings, making the stock a high‑risk, high‑reward play. Monitoring legal developments, FDA rulemaking, and the Q2 earnings release will be essential to gauge the stock’s true trajectory.
Frequently Asked Questions About HIMS
How should one interpret Hims & Hers Health (HIMS) valuation relative to its peers?
At a forward P/E of 56.96, HIMS trades above the peer average of 53.0, reflecting expectations of a turnaround following its peptide acquisition. The valuation gap indicates that the market is pricing in significant upside from new product lines and AI services. Analysts argue that the premium is justified by the company’s strong online presence and potential for recurring revenue. Nonetheless, the high multiple also amplifies downside risk if growth stalls. A careful assessment of earnings volatility and regulatory risk is warranted when comparing HIMS to its peers.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
